Clinical Advisory Board

Joseph P. Broderick, MD

Joseph P. Broderick, MD, is Professor of Neurology and Rehabilitation Medicine at the University of Cincinnati College of Medicine and Director of the University of Cincinnati Gardner Neuroscience Institute. Dr. Broderick is an internationally recognized expert on the treatment and underlying causes of stroke. He currently is the Principal Investigator of the National Coordinating Center for the U.S. NIH funded network of stroke trials.

Read More
Professor Bruce Campbell

Professor Campbell, the head of stroke care at Royal Melbourne Hospital, is regarded as a leading international expert in stroke research and practice implementation. His research interests are focused on the imaging and treatment of acute stroke and he was co-principal investigator and medical coordinator of the EXTEND-IA and EXTEND-IA TNK multi-center randomized trials published in the New England Journal of Medicine in 2015 and 2018. He co-chairs the World Stroke Organization Young Stroke Professionals Committee.

Read More
Richard Becker, MD

Richard Becker, MD is Professor of Medicine and Director, Heart, Lung and Vascular Institute at The University of Cincinnati College of Medicine and an Adjunct Professor of Medicine at the Duke University School of Medicine. His experience as a physician-scientist spans the molecular, mechanistic and drug development perspectives of cardiovascular disease. He has served on multiple industry sponsored Scientific and Clinical Advisory Boards focused on the development of anti-thrombotic drugs and reversal agents.

Read More
Pooja Khatri MD, MSc

Pooja Khatri MD, MSc is Professor of Neurology and Director of the Stroke Team at University of Cincinnati. She has had over 15 years of federal and industry funding, and specific expertise in developing stroke reperfusion therapies from conception to post-marketing. She co-directs the National Coordinating Center for the U.S. NIH StrokeNet.

Read More
Dr. Michael Hill

Dr. Michael Hill is a Professor for the Departments of Clinical Neurosciences, Community Health Sciences, Medicine and Radiology at the University of Calgary and Director of the Stroke Unit for the Calgary Stroke Program, Alberta Health Services. Dr. Hill’s research interests include stroke thrombolysis, stroke epidemiology, and surveillance and clinical trials. He is currently leads the largest ongoing Phase 3 trial in ischemic stroke.

Read More
Robert Harrington, MD

Dr. Harrington served as president of the American Heart Association (AHA) for 2019-20. He is a world-renowned interventional cardiologist and clinical investigator in the area of heart disease and Arthur L. Bloomfield Professor of Medicine and Chairman of the Department of Medicine at Stanford University.

Read More
Ashutosh Jadhav, MD, PhD

Ashutosh Jadhav, MD, PhD, is a vascular and interventional neurologist at Barrow Neurological Institute. serves on the AHA Stroke Council. Dr. Jadhav’s research focuses on acute ischemic stroke and has published more than 200 peer-reviewed articles. Dr. Jadhav has served on the steering committee on numerous randomized controlled trials as well as site principal investigator of multiple clinical trials investigating new strategies for stroke treatment. He is the founding Editor-in-Chief of Stroke: Vascular and Interventional Neurology.

Read More
Dr. Tudor Jovin

Dr. Jovin is an expert in the interventional and non-interventional treatment for the entire spectrum of stroke and cerebrovascular disorders. He has served as principal investigator for several international clinical studies including REVASCAT, a randomized trial of endovascular therapy versus medical therapy for acute stroke within eight hours of symptoms onset conducted in Spain, and DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond eight-hour time window. Both studies are considered landmark studies in the development of treatments for acute stroke and have been published in the New England Journal of Medicine. The consequential nature of his research is evidenced by recently published studies that have identified Dr. Jovin as the highest impact author in the neuro-interventional field.

Read More